Date: 2014-10-13
Type of information: Distribution agreement
Compound: Fycompa® (perampanel)
Company: Eisai (Japan) Hikma Pharmaceuticals
Therapeutic area: CNS diseases - Neurological diseases
Type agreement: distribution
Action mechanism:
Disease: adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older
Details: * On October 13, 2014, Hikma Pharmaceuticals announced a partnership with Eisai for the distribution of Fycompa® (perampanel), Eisai’s first-in-class epilepsy treatment, in the Middle East. The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015. Perampanel is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. Countries covered by the five year partnership will include the Kingdom of Saudi Arabia, United Arab Emirates, Jordan, Kuwait, Bahrain, Oman, Qatar, Sudan, Iraq, Libya and Yemen. Perampanel was approved by the European Commission on 23 July 2012 and the FDA on 22 October 2012. Discovered and developed by Eisai in Europe and Japan, perampanel is manufactured in the UK.
Financial terms:
Latest news:
